Announcement

Collapse
No announcement yet.

Gdf-8

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Gdf-8

    New drugs will be following for sure:

    Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.

    McPherron AC, Lawler AM, Lee SJ.

    Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

    The transforming growth factor-beta (TGF-beta) superfamily encompasses a large group of growth and differentiation factors playing important roles in regulating embryonic development and in maintaining tissue homeostasis in adult animals. Using degenerate polymerase chain reaction, we have identified a new murine TGF-beta family member, growth/differentiation factor-8 (GDF-8), which is expressed specifically in developing and adult skeletal muscle. During early stages of embryogenesis, GDF-8 expression is restricted to the myotome compartment of developing somites. At later stages and in adult animals, GDF-8 is expressed in many different muscles throughout the body. To determine the biological function of GDF-8, we disrupted the GDF-8 gene by gene targeting in mice. GDF-8 null animals are significantly larger than wild-type animals and show a large and widespread increase in skeletal muscle mass. Individual muscles of mutant animals weigh 2-3 times more than those of wild-type animals, and the increase in mass appears to result from a combination of muscle cell hyperplasia and hypertrophy. These results suggest that GDF-8 functions specifically as a negative regulator of skeletal muscle growth.

    PMID: 9139826 [PubMed - indexed for MEDLINE]

    Enjoy...
    "That damn log book"

    www.trueprotein.com Highest quality protein at the lowest price...

  • #2
    This will be the drug from Wyeth:

    Wyeth is moving forward with MYO-029, a human monoclonal antibody discovered by CAT in collaboration with Wyeth and licensed to Wyeth, that neutralises the effects of a protein called GDF-8, which is associated with reduced skeletal muscle mass. MYO-029 is being studied as a potential therapy for muscle-wasting diseases, including muscular dystrophy, an inherited disease that causes degeneration of various muscle groups, and sarcopenia, which is a loss of muscle mass and strength that can result from ageing or from disease such as cancer.

    So far it looks like its only been teasted for the last 6 months or so...
    "That damn log book"

    www.trueprotein.com Highest quality protein at the lowest price...

    Comment

    Working...
    X